Clinical experience with azlocillin in the treatment of urinary tract infections with Pseudomonas aeruginosa.
27 patients, aged 19-23 yr, with symptomatic urinary tract infection or epididymitis due to Pseudomonas aeruginosa were treated with azlocillin. All pseudomonas strains were sensitive to azlocillin. The microorganism was eradicated in 25/26 evaluable patients. 25/27 patients were clinically cured. Bacteriological relapse occurred in 11 patients. No serious drug reactions were noted.
D000328:Adult; D000368:Aged; D001390:Azlocillin; D004823:Epididymitis / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D010406:Penicillins; D001390:Azlocillin